Clinical Research

Clinical Research

Harrington Cancer Center is committed to clinical research that can provide valuable information and better outcomes for cancer patients. Participation in clinical research allows our physicians to offer the most current and most effective cancer trials available which may provide patients with additional treatment options.

Clinical trials represent the final stage of a long research process that begins in the laboratory. After it has been determined that the research is safe for human application, then a clinical trial can be designed that will:

  • Test the safety and effectiveness of new drugs and new methods.
  • Test new approaches to the use of these drugs.
  • Investigate the benefits of enhanced surgical methods and radiation therapy techniques.
  • Identify the most effective treatments with the least amount of side effects

The Harrington Cancer Center has received national & state recognition for its participation and enrollment to national cancer prevention trials including STAR (Breast Cancer Prevention) and SELECT (Prostate Cancer Prevention).

Harrington Cancer Center is a member of the Southwest Oncology Group (SWOG), one of the largest of the National Cancer Institute-supported cancer clinical trials cooperative groups. SWOG's primary mission is clinical research in the prevention and cure of cancer.

Click here to view the current Harrington Cancer Center Clinical Trials

Patients may also search for trials open at different sites on  https://ClinicalTrials.gov.
ClincalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.  

Contact Information

For information about clinical trials currently underway at Harrington Cancer Center, please contact Gina Cravey, RN, CCRC at gcravey@harringtoncc.org or 806-212-1985.

*Harrington Cancer Center receives some of its funding for research from a Public Health Service (PHS) grant, and is required to post the following policy:  Notice of Financial Conflict of Interest Policy